A recent study by Massachusetts General Hospital found that combining osteoporosis treatments does not produce better results. Injections of PTH, a treatment initially developed through MGH research, increase bone formation and were superior to alendronate alone in improving bone density.
The study found that initiating Avonex treatment immediately after MS symptoms appeared reduced the development of clinically definite MS by 35% and relapses by 48% compared to delayed initiation. Early intervention also led to higher likelihood of being classified as clinically stable between years four and five.
A new study found that combining osteoporosis medications, parathyroid hormone and bisphosphonates, does not provide additional benefits to patients. The trial of 238 postmenopausal women showed no significant improvement in bone density or anabolic effects when both drugs were used together.